Vistagen Therapeutics Inc. Reports Recent Stock Performance

Vistagen Therapeutics, Inc., a clinical-stage biopharmaceutical company based in South San Francisco, United States, has recently seen fluctuations in its stock performance. The company, which specializes in developing medications for central nervous system-related diseases and disorders, is listed on the Nasdaq stock exchange.

As of July 1, 2025, Vistagen Therapeutics’ stock closed at $2.04. This price reflects a significant movement from its 52-week low of $1.90, recorded on April 8, 2025. The stock reached its 52-week high of $4.21 on July 10, 2024, indicating a period of volatility over the past year.

Vistagen Therapeutics serves a global market, providing innovative treatments to patients and healthcare professionals worldwide. The company’s focus remains on addressing unmet medical needs within the central nervous system domain, aiming to improve patient outcomes through its clinical-stage developments.

For more information about Vistagen Therapeutics and its ongoing projects, stakeholders and interested parties can visit the company’s website at www.vistagen.com .

The company continues to navigate the challenges and opportunities within the biotechnology sector, maintaining its commitment to advancing healthcare solutions for central nervous system disorders.